Using a new imaging and therapy approach for metastatic tumors
Diagnosis of Metastatic Tumors on 68Ga-FAPI-RGD PET-CT and Radioligand Therapy
This study is testing a new treatment and imaging method for patients with metastatic tumors to see if it can help improve diagnosis and treatment outcomes.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 15 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | Peking Union Medical College Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT06638034 on ClinicalTrials.gov |
What this trial studies
This study investigates the use of a novel dual-targeted therapeutic drug, 177Lu-FAPI-RGD, for patients with metastatic tumors that express fibroblast activation protein (FAP) and RGD. It aims to improve tumor diagnosis through advanced imaging techniques using 68Ga-FAPI-RGD PET-CT, which targets both FAP and integrin αvβ3 receptors. The study will assess the safety and therapeutic response of this treatment in patients with confirmed metastatic tumors. This is the first time this dual-targeted approach is being tested in a clinical setting.
Who should consider this trial
Good fit: Ideal candidates include patients with confirmed treated or untreated metastatic tumors who have undergone specific imaging within the last two weeks.
Not a fit: Patients who are pregnant, breastfeeding, or have medical conditions that may interfere with study compliance will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly enhance the diagnosis and treatment of metastatic tumors, leading to better patient outcomes.
How similar studies have performed: While this approach is novel, similar studies using targeted therapies and imaging have shown promise in other contexts.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * confirmed treated or untreated metastatic tumors patients; * 68Ga-FAPI PET/CT and 18F-FDG PET/CT within two weeks; * signed written consent. Exclusion Criteria: * pregnancy; * breastfeeding; * any medical condition that in the opinion of the investigator may significantly interfere with study compliance
Where this trial is running
Beijing, Beijing Municipality
- Chinese Academy of Medical Science & Peking Union Medical College Hospital — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Study coordinator: Zhaohui Zhu, MD
- Email: 13611093752@163.com
- Phone: 13611093752
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.